Robert Vonderheide, MD
Enriched profileDirector, Abramson Cancer Center; John H. Glick, MD, Abramson Cancer Center's Director Professor; Vice Dean for Cancer Programs, Perelman School of Medicine; Vice President for Cancer Programs, University of Pennsylvania Health System · University of Pennsylvania
Robert Vonderheide is Director, Abramson Cancer Center; John H. Glick, MD, Abramson Cancer Center's Director Professor; Vice Dean for Cancer Programs, Perelman School of Medicine; Vice President for Cancer Programs, University of Pennsylvania Health System at University of Pennsylvania. OpenAlex indexes 800 publications with 45,666 citations (h-index 99); ClinicalTrials.gov lists 6 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Robert H. Vonderheide, MD, is Director, Abramson Cancer Center at University of Pennsylvania, Perelman School of Medicine / Abramson Cancer Center. The public record shows 800 publications with 45,666 citations (h-index 99), centered on Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Immunotherapy and Immune Responses. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 4 companies, 9 NIH-funded awards (2001–2026).
- Most recent indexed publication: 2026 · JMIR formative research
- Top research focus: Cancer Immunotherapy and Biomarkers
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 4 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 28 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 196.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors
Sponsor: Abramson Cancer Center at Penn Medicine
Industry payments
Updated 27 Aug 2026
4 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:
- Lilly USA, LLCProgram year20251 payment
- EMD Serono Research & Development Institute, Inc.Program year20241 payment
- E.R. Squibb & Sons, L.L.C.Program year20231 payment
NIH funding
Updated 27 Aug 2026
9 NIH research awards on record, funded 2001–2026 per NIH RePORTER. The latest:
- Changing the natural history of pancreatic ductal adenocarcinoma with cancer interception strategies
University of Pennsylvania
FY2026$658,033R01CA303474
Congress activity
Updated 27 Aug 2026
91 congress contributions (2005–2026) across AACR, ASCO, SABCS per OpenAlex. The most recent:
- Abstract LB406: Active RAS inhibition intercepts pancreas cancer in mice
AACR Annual Meeting
AACR2026Co-authorLate-breaking
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Influence of Tumor-Draining Lymph Nodes on Immunotherapy: Lymphadenectomy May Have Its Limits.
Clinical cancer research
Article2026 - KRAS Inhibitors in Pancreas Cancer: Facts and Hopes about the Immunotherapy We Have All Been Waiting for.
Clinical cancer research
Review2026 - Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma.
Science (New York, N.Y.)
Article2026
Most-cited works
by citation count (OpenAlex)- 01Understanding the tumor immune microenvironment (TIME) for effective therapy6,057 citations2018
- 02
- 03
- 04EMT and Dissemination Precede Pancreatic Tumor Formation2,118 citations2012
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/robert-vonderheide-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/robert-vonderheide-990099355
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Robert-H-Vonderheide-39694462
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
bcrf.org/blog/blog-2024-podcast-robert-vonderheide-bcrf
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org ↗ - Other
moffitt.org/about-moffitt/podcasts/immunoverse/from-kras-to-cd40
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - X / Twitter
x.com/PC3Innovation/status/2034691520272478326
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
- Internal Medicine residency
Massachusetts General Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗ - Medical Oncology fellowship
Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aacr.org ↗
Secondary affiliations
appointments beyond the home institution- Basser Center for BRCA
University of Pennsylvania
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aacrjournals.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →parkerici.org ↗
- Center for Cellular Immunotherapies
Perelman School of Medicine (Vonderheide Lab)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
Media & interviews
press, podcasts and appearances- NBC News feature on pancreatic cancer mRNA vaccine trial results
quoted discussing immunotherapy mechanism shift
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nbcnews.com ↗ - Guest
Moffitt Cancer Center's ImmunoVerse podcast, "From KRAS to CD40: Advancing Pancreatic Cancer Immunotherapy"
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Q&A interview
"Robert Vonderheide on Immunotherapy Advances," Cancer Discovery (AACR journal)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacrjournals.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Harold Feldman, MD
University of Pennsylvania
Howard Herrmann, MD
University of Pennsylvania
Corey Langer, MD
University of Pennsylvania